Originally posted by strangelogic:
↑
Firstly, great to see PNV getting good marketing exposure.
Expand
"I think it is also wise to remember that biomedical products are notoriously difficult to get through regulation and then become accepted best practice. The medical community is rightly cautious and slower to adopt innovation than most other markets. "
This has been my point all along.
strangelogic, what are your opinions on BTMs ability to penetrate the US market for the near future?
(20min delay)